Visacor

Valsts: Jaunzēlande

Valoda: angļu

Klimata pārmaiņas: Medsafe (Medicines Safety Authority)

Aktīvā sastāvdaļa:

Rosuvastatin calcium 20.8mg equivalent to 20 mg rosuvastatin;  

Pieejams no:

AstraZeneca Limited

SNN (starptautisko nepatentēto nosaukumu):

Rosuvastatin calcium 20.8 mg (= 20 mg rosuvastatin)

Deva:

20 mg

Zāļu forma:

Film coated tablet

Kompozīcija:

Active: Rosuvastatin calcium 20.8mg equivalent to 20 mg rosuvastatin   Excipient: Calcium phosphate Crospovidone Hypromellose as Opadry Pink Iron oxide red as Opadry Pink Lactose monohydrate as Opadry Pink   Magnesium stearate Microcrystalline cellulose Titanium dioxide as Opadry Pink Triacetin as Opadry Pink

Vienības iepakojumā:

Blister pack, Al/Al foil, 30 tablets

Klase:

Prescription

Receptes veids:

Prescription

Ražojis:

AstraZeneca UK Ltd

Ārstēšanas norādes:

VISACOR is indicated to: - Reduce elevated LDL-C, Total Cholesterol, triglycerides and to increase HDLcholesterol in patients with primary hypercholesterolemia (heterozygous familial and non familial) and mixed dyslipidaemia (Fredrickson Types IIa and IIb). - Treat isolated hypertriglyceridaemia (Fredrickson Type IV hyperlipidaemia). Reduce Total Cholesterol and LDL-C in patients with homozygous familial hypercholesterolemia, as an adjunct to diet and other lipid lowering treatments (eg. LDL apheresis) or alone if such treatments are unavailable.

Produktu pārskats:

Package - Contents - Shelf Life: Blister pack, Al/Al foil - 30 tablets - 36 months from date of manufacture stored at or below 30°C

Autorizācija datums:

2009-07-31